Activity of a 0.05% triamcinolone acetonide/laurocapram formulation: double-blind, randomized comparison with standard 0.1% triamcinolone acetonide creams and with mild (Class VI) to potent (Class III) topical corticosteroids

Since the usefulness of topical corticosteroids in the treatment of ulcerative colitis was first reported1 double-blind trials have confirmed their effectiveness, and they are now widely used.2 For disease localised to the rectum suppositories, and for more extensive disease, retention enemas containing various corticosteroids are available (see table). In severe cases these preparations also valuably supplement systemic corticosteroid therapy, with or without sulphasalazine (Salazopyrin).

Download Full-text

Relapse recovery

Neurology Neuroimmunology & Neuroinflammation ◽

10.1212/nxi.0000000000000653 ◽

2019 ◽

Vol 7 (2) ◽

pp. e653 ◽

Cited By ~ 4

Author(s):

Orhun H. Kantarci ◽

Burcu Zeydan ◽

Elizabeth J. Atkinson ◽

Brittani L. Conway ◽

Carmen Castrillo-Viguera ◽

...

Keyword(s):

Term Treatment ◽

Benign Disease ◽

Good Recovery ◽

Class Iii ◽

Early Recovery ◽

Double Blind ◽

Delayed Treatment ◽

Long Term Treatment ◽

Edss Score

ObjectiveTo determine whether basing the decision to initiate immediate vs delayed disease-modifying therapy (DMT) on extent of recovery after initial relapse affects long-term disability accumulation in a multiple sclerosis (MS) evidence-based setting.MethodsWe analyzed the double-blind, placebo-controlled interferon beta-1a 30 mc once a week in clinically isolated syndrome and 10-year-follow-up extension trial. Good recovery after presenting relapse was defined as (1) full early recovery within 28 days of symptom onset (Expanded Disability Status Scale [EDSS] score of 0 at enrollment maintained ≥6 months) and (2) delayed good recovery (EDSS score > 0 at enrollment and improvement from peak deficit to 6th-month or 1-year visit ≥ median). Time from recovery assignment to future disability (EDSS score ≥ 2.5 or ≥4.0) was studied on a relapse-recovery-stratified age axis and immediate vs 3-year delayed treatment initiation with Kaplan-Meier statistics and hazard ratios (HRs).ResultsOne hundred seventy-five/328 patients had good recovery (94 immediate and 81 delayed treatment); 153 did not have good recovery (77 immediate and 76 delayed treatment). HRs for EDSS score ≥2.5 outcome were: delayed treatment without good recovery as reference (HR = 1.0), delayed treatment with good recovery (HR6th-month: 0.67, p = 0.207; HR1st-year: 0.40, p = 0.027), immediate treatment without good recovery (HR6th-month: 0.56, p = 0.061; HR1st-year: 0.40, p = 0.011), and immediate treatment with good recovery (HR6th-month: 0.43, p = 0.014; HR1st-year: 0.48, p = 0.034). Placebo patients were switched to long-term treatment after 3 years, and insufficient EDSS score ≥4.0 outcome events were available to study.ConclusionsIn patients with MS presenting without good recovery after the initial relapse, immediate DMT initiation favorably influences the likelihood of more ambulatory-benign disease akin to patients with good recovery after the initial relapse.Classification of evidenceThis study provides Class III evidence that for patients with MS without good recovery after the initial relapse, immediate DMT initiation increases the likelihood of a benign disease course.

Download Full-text

A Short-Term Double-Blind Trial of Aerosol Triamcinolone Acetonide in Steroid-Dependent Patients with Severe Asthma

CHEST Journal ◽

10.1378/chest.69.4.455 ◽

1976 ◽

Vol 69 (4) ◽

pp. 455-460 ◽

Cited By ~ 12

Author(s):

Robert J. Kriz ◽

Frank Chmelik ◽

Guillermo doPico ◽

Charles E. Reed

Keyword(s):

Triamcinolone Acetonide ◽

Severe Asthma ◽

Double Blind Trial ◽

Short Term ◽

Double Blind ◽

Blind Trial ◽

Steroid Dependent

Download Full-text

Topical Treatment of Eczema with Triamcinolone Acetonide Benzoyl-β-Amino-Isobutyrate: A Double-Blind Comparison with Betamethasone Dipropionate

Journal of International Medical Research ◽

10.1177/030006057700500311 ◽

1977 ◽

Vol 5 (3) ◽

pp. 207-212

Author(s):

F E Roessei

Keyword(s):

Triamcinolone Acetonide ◽

Topical Treatment ◽

Betamethasone Dipropionate ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Blind Comparison

The results are reported of a double-blind study of the topical efficacy of triamcinolone acetonide benzoyl-β-amino-isobutyrate (TBI), in 21 patients with symmetrically paired lesions of acute eczema. The effects were compared with those of betamethasone dipropionate. On the indication chosen, the two corticosteroids were equally efficacious; tolerance, also, was the same for both substances.

Download Full-text

Topical Corticosteroids a Viable Solution for Oral Graft versus Host Disease? A Systematic Insight on Randomized Clinical Trials

Medicina ◽

10.3390/medicina56070349 ◽

2020 ◽

Vol 56 (7) ◽

pp. 349

Author(s):

Arin Sava ◽

Andra Piciu ◽

Sergiu Pasca ◽

Alexandru Mester ◽

Ciprian Tomuleasa

Keyword(s):

Clinical Trials ◽

Graft Versus Host Disease ◽

Randomized Clinical Trials ◽

Open Label ◽

Double Blind ◽

Host Disease ◽

Graft Versus Host ◽

Overall Response ◽

Topical Corticosteroids ◽

Oral Gvhd

Background and Objectives: This research attempts to provide a clear view of the literature on randomized clinical trials (RCTs) concerning the efficacy of topical dexamethasone, clobetasol and budesonide in oral graft versus host disease (GVHD). Materials and Methods: An electronic search of the PubMed, Web of Science and Scopus databases was carried out for eligible RCTs. Studies were included if they had adult patients with oral GVHD treatment with topical corticosteroids, and if the RCT study was published in English. The Cochrane Risk of Bias tool was used to assess the quality of these studies. Overall, three RCTs were included (an Open, Randomized, Multicenter Trial; a Randomized Double-Blind Clinical Trial; and an Open-Label Phase II Randomized Trial). Results: The trials involved 76 patients, of which 44 patients received topical dexamethasone, 14 patients received topical clobetasol and 18 patients received topical budesonide. Topical agents were most frequently used when oral tissues were the sole site of involvement. It appears that the best overall response is present for budesonide with no difference between the four arms, followed by clobetasol, and then by dexamethasone. The limitation of the current study is mainly represented by the fact that overall response was derived in two of the studies from other parameters. Moreover, both budesonide and clobetasol were used in only one study each, while two assessed dexamethasone. Conclusions: Based on the clinical trials, all three agents seem to be effective in treating oral GVHD and had a satisfactory safety profile. There is still a need for assessing high quality RCTs to assess the efficacy of these therapies on a larger cohort.

Download Full-text